- Home
- ZDGE vs XGN Comparison
ZDGE vs XGN Comparison
Compare ZDGE & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- XGN
- Stock Information
- Founded
- ZDGE 2008
- XGN 2002
- Country
- ZDGE United States
- XGN United States
- Employees
- ZDGE N/A
- XGN N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- XGN Medical Specialities
- Sector
- ZDGE Technology
- XGN Health Care
- Exchange
- ZDGE Nasdaq
- XGN Nasdaq
- Market Cap
- ZDGE 51.8M
- XGN 49.4M
- IPO Year
- ZDGE N/A
- XGN 2019
- Fundamental
- Price
- ZDGE $3.67
- XGN $3.03
- Analyst Decision
- ZDGE
- XGN Buy
- Analyst Count
- ZDGE 0
- XGN 1
- Target Price
- ZDGE N/A
- XGN $7.00
- AVG Volume (30 Days)
- ZDGE 47.6K
- XGN 33.9K
- Earning Date
- ZDGE 10-24-2024
- XGN 11-11-2024
- Dividend Yield
- ZDGE N/A
- XGN N/A
- EPS Growth
- ZDGE N/A
- XGN N/A
- EPS
- ZDGE N/A
- XGN N/A
- Revenue
- ZDGE $29,142,000.00
- XGN $56,660,000.00
- Revenue This Year
- ZDGE $13.67
- XGN $9.98
- Revenue Next Year
- ZDGE $13.41
- XGN $13.63
- P/E Ratio
- ZDGE N/A
- XGN N/A
- Revenue Growth
- ZDGE 4.15
- XGN 7.05
- 52 Week Low
- ZDGE $1.70
- XGN $1.30
- 52 Week High
- ZDGE $5.18
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- ZDGE 61.16
- XGN 53.18
- Support Level
- ZDGE $3.34
- XGN $2.90
- Resistance Level
- ZDGE $3.75
- XGN $3.18
- Average True Range (ATR)
- ZDGE 0.21
- XGN 0.17
- MACD
- ZDGE 0.06
- XGN -0.02
- Stochastic Oscillator
- ZDGE 88.68
- XGN 65.12
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.